Correlation Engine 2.0
Clear Search sequence regions

  • adult (1)
  • antigen (4)
  • b virus (7)
  • e antigen (8)
  • entecavir (3)
  • female (1)
  • help (1)
  • humans (1)
  • patients (1)
  • rna (4)
  • serum (1)
  • Sizes of these terms reflect their relevance to your search.

    The RNA interference (RNAi) drug ARC-520 was shown to be effective in reducing serum hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) in HBeAg-positive patients treated with a single dose of ARC-520 and daily nucleosidic analogue (entecavir). To provide insights into HBV dynamics under ARC-520 treatment and its efficacy in blocking HBV DNA, HBsAg, and HBeAg production we developed a multi-compartmental pharmacokinetic-pharamacodynamic model and calibrated it with frequent measured HBV kinetic data. We showed that the time-dependent single dose ARC-520 efficacies in blocking HBsAg and HBeAg are more than 96% effective around day 1, and slowly wane to 50% in 1-4 months. The combined single dose ARC-520 and entecavir effect on HBV DNA was constant over time, with efficacy of more than 99.8%. The observed continuous HBV DNA decline is entecavir mediated, the strong but transient HBsAg and HBeAg decays are ARC-520 mediated. The modeling framework may help assess ongoing RNAi drug development for hepatitis B virus infection.


    Sarah Kadelka, Harel Dahari, Stanca M Ciupe. Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection. Scientific reports. 2021 Jan 08;11(1):200

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 33420293

    View Full Text